“We had been working in the muscarinic receptor space for almost 20 years,” says Samir Siddhanti, Neurocrine’s executive director of business development. The Neurocrine team was aware of ...

At present no definitive medical treatment exists for acute pancreatitis. [9,10] Pirenzepine has shown encouraging positive responses and a low incidence of adverse effects when used to treat ...

Developed by Karuna Therapeutics, recently acquired by Bristol Myers Squibb, Cobenfy diverges from the industry’s dopamine-dominated approach, targeting muscarinic acetylcholine receptors instead.

Researchers from Maplight Therapeutics Inc. presented preclinical data for the investigational muscarinic M1/M4 receptor agonist ML-007, being evaluated for the treatment of neuropsychiatric disorders ...

The M1/M4 muscarinic receptor agonist is vying to be the first drug to reach the market for schizophrenia with a new mechanism of action in decades. It is also in phase 3 clinical testing as an ...

Emraclidine gave AbbVie entry into a group of companies developing drugs targeting muscarinic receptors, which are receptors in the central nervous system that play key roles in neuronal functions.

TRN-157 is under clinical development by Theron Pharmaceuticals and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD).

An antipsychotic drug approved last month by the FDA changes that. It triggers muscarinic receptors instead of dopamine receptors. The drug is the result of a chance scientific finding ...

Diverging from the traditional dopamine-based therapies, Cobenfy is said to address the critical gaps in the current treatments by targeting muscarinic acetylcholine receptors. Its success can ...